Sign in

You're signed outSign in or to get full access.

Leonard Sokolow

Director at Vivos Therapeutics
Board

About Leonard J. Sokolow

Leonard J. Sokolow, age 68, has served as an independent director of Vivos Therapeutics since June 2020, and is the Audit Committee chair and designated audit committee financial expert. He holds a B.A. and J.D. from the University of Florida, an LL.M. in Taxation from NYU School of Law, and is a Certified Public Accountant; he is currently co-CEO of SKYX Platforms Corp. and has extensive executive experience across financial services and public company governance .

Past Roles

OrganizationRoleTenureCommittees/Impact
SKYX Platforms Corp. (Nasdaq: SKYX)Co-Chief Executive Officer; DirectorCo-CEO since Sep 2023; director since 2015Senior operator; board-level governance
Newbridge Financial, Inc.Chief Executive Officer & President2015–Aug 2023Led financial services holding company
Newbridge Securities Corporation / Newbridge Financial Services GroupChairman (2015–Jul 2022); CEO (Aug 2022–Aug 2023)2015–Aug 2023Broker-dealer and RIA leadership
National Holdings Corporation (public)President & Vice Chairman2008–2012Financial services executive role
vFinance Inc. (public)CEO & President; later Chairman & CEO1999–2008; Jan 2007–Jul 2008Co-founder; led through merger into National Holdings
Americas Growth Fund Inc.Founder, Chairman & CEO1994–1998Closed-end registered investment company leadership
Applica Inc. (public)EVP & General Counsel1988–1993Legal, compliance and corporate governance
Ernst & Young; KPMG Peat MarwickCertified Public Accountant1980–1982Audit/accounting foundations

External Roles

OrganizationRoleSinceCommittees/Impact
Consolidated Water Co. Ltd. (Nasdaq: CWCO)Director; Audit Committee Chair; Nominating & Corporate Governance Committee memberDirector since 2006; Nom/Gov since 2011Audit leadership; governance oversight
SKYX Platforms Corp.Co-CEO; DirectorCo-CEO since Sep 2023; Director since 2015Executive management; board service
Agrify Corporation (Nasdaq: AGFY)DirectorSince Dec 2021Audit Committee and Compensation Committee member

Board Governance

  • Independence: The Board affirmatively determined Sokolow is independent under Nasdaq rules; he serves alongside five independent directors .
  • Committee assignments: Audit Committee Chair and “audit committee financial expert”; member of Nominating & Corporate Governance Committee .
  • Attendance and engagement: In FY2024 the Board met 7 times, the Audit Committee met 5 times, the Compensation Committee met 7 times, and the Nominating & Corporate Governance Committee did not meet; directors attended 97% of meetings. All directors attended the last annual meeting (Nov 26, 2025) .
  • Leadership structure: No lead independent director; independent directors hold regular executive sessions, providing a forum for management-free oversight .
Governance MetricFY 2024Notes
Board meetings held7 Broad operational oversight
Audit Committee meetings held5 Financial reporting, auditor oversight
Compensation Committee meetings held7 Incentive plan and pay risk oversight
Nominating & Corporate Governance Committee meetings held0 Charter responsibilities remain active
Director meeting attendance97% High engagement signal
Annual meeting attendance100% of directors (Nov 26, 2025) Shareholder engagement

Fixed Compensation

ComponentAmount (USD)Basis/Notes
Annual cash retainer$48,000 Standard for non-employee directors
Committee chair fee (Audit)$10,000 Audit Chair
Committee membership fee (Nominating & Governance)$5,000 Committee member
Total cash fees (FY2024 actual)$63,000 Matches program structure
Meeting fees$0 No meeting fees policy

Performance Compensation

| Award Type | Grant Detail | Fair Value (USD) | Vesting/Metrics | |---|---|---| | Stock options (director award) | FY2024 option grant | $7,840 | Grant-specific vesting terms not disclosed for directors; Company equity plans allow options, RSUs, performance units under the 2024 Omnibus Plan |

  • Equity plan backdrop: 2024 Omnibus Plan authorizes stock options, SARs, restricted stock, RSUs, and performance units; share pool increased pending stockholder approval from 1,600,000 to 4,100,000 shares .

Other Directorships & Interlocks

CompanyRelationship to VVOSPotential Conflict/Interlock Assessment
Consolidated Water (CWCO)Unrelated industry (water utility)No competitive overlap; governance experience additive
SKYX Platforms (SKYX)Unrelated industry (consumer technology/lighting)Time-commitment risk as co-CEO; low direct competitive overlap with VVOS
Agrify (AGFY)Unrelated industry (cannabis tech)No competitive overlap; historical board committees broaden governance depth

Expertise & Qualifications

  • CPA; JD and LL.M (Taxation); extensive executive and board leadership across financial services and public companies .
  • Designated “audit committee financial expert” under SEC/Nasdaq standards .
  • Chairs VVOS Audit Committee and signed the FY2024 Audit Committee Report recommending inclusion of audited financials in Form 10-K .

Equity Ownership

MeasureValue
Total beneficial ownership (shares)6,800 (includes options exercisable within 60 days)
Ownership % of outstanding sharesLess than 1%
Options – exercisable vs. unexercisable6,800 exercisable within 60 days; unexercisable not disclosed for director
Shares pledged as collateralNone disclosed
Stock ownership guidelinesNot disclosed
Hedging/pledging policyInsider Trading Policy in place; board-level adoption and pre-clearance requirement

Governance Assessment

  • Strengths

    • Independent director with deep financial, legal, and audit expertise; serves as Audit Committee Chair and SEC-defined financial expert—supports robust oversight of reporting, controls, and auditor independence .
    • High engagement: 97% attendance in FY2024 and full director attendance at the annual meeting—positive signal for accountability and investor relations .
    • Beneficial ownership aligns incentives (exercisable options); no pledging or related-party transactions disclosed—limits conflict risk .
  • Risks and watch items

    • Time commitment: Concurrent co-CEO role at SKYX could pose bandwidth risk; monitor meeting attendance and committee workload to ensure continued effectiveness .
    • Board has no lead independent director; while executive sessions occur, a formal lead role could strengthen independent oversight in a combined chair/CEO structure .
    • Nominating & Corporate Governance Committee reviews director compensation arrangements; while all members are independent, oversight of pay by a committee including board members requires continued rigor to avoid pay inflation or misalignment .
  • Controls and policies

    • Audit Committee charter authorizes pre-approval of audit/non-audit services and review/approval of related party transactions, providing structural safeguards against conflicts .
    • Company-wide clawback policy (Section 10D-compliant) and insider trading policy updates enhance governance posture, though clawback applies to certain officers rather than directors .